Lys607

Site Information
ANMERIMkAQALrDN SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 8107214
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 )
Disease tissue studied:	breast cancer ( 13 , 17 , 18 ) , breast cancer, surrounding tissue ( 13 ) , cervical cancer ( 2 ) , colorectal cancer ( 2 ) , colorectal carcinoma ( 2 ) , esophageal cancer ( 16 , 21 ) , esophageal cancer, surrounding tissue ( 14 ) , gastric cancer ( 9 ) , leukemia ( 2 ) , chronic myelogenous leukemia ( 2 ) , liver cancer ( 2 , 19 , 20 , 22 ) , liver cancer, surrounding tissue ( 15 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 , 5 , 6 , 8 , 10 , 11 ) , non-small cell lung adenocarcinoma ( 2 , 6 ) , non-small cell squamous cell lung carcinoma ( 11 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 2 , 8 ) , breast ( 13 , 17 , 18 ) , esophagus ( 14 , 16 , 21 ) , HCT116 (intestinal) ( 3 , 12 ) , HeLa (cervical) ( 2 , 7 ) , HeLa S3 (cervical) ( 4 ) , Jurkat (T lymphocyte) ( 23 , 24 ) , K562 (erythroid) ( 2 ) , Kyse150 (esophageal) [SMYD2 (human), knockdown] ( 1 ) , Kyse150 (esophageal) ( 1 ) , liver ( 2 , 15 , 19 , 20 , 22 ) , MKN-45 (gastric) ( 9 ) , NCI-H1703 (squamous) ( 11 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H3122 (pulmonary) ( 5 ) , NCI-H3255 (pulmonary) ( 10 ) , SMMC7721 (hepatocyte) ( 2 ) , SW620 (intestinal) ( 2 )

References
1	Olsen JB, et al. (2016) Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics. Mol Cell Proteomics 15, 892-905 26750096 Curated Info
2	Wu Z, et al. (2015) A chemical proteomics approach for global analysis of lysine monomethylome profiling. Mol Cell Proteomics 14, 329-39 25505155 Curated Info
3	Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87 24129315 Curated Info
4	Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47 23748837 Curated Info
5	Rikova K (2013) CST Curation Set: 18853; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
6	Rikova K (2013) CST Curation Set: 18852; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
7	Cao XJ, Arnaudo AM, Garcia BA (2013) Large-scale global identification of protein lysine methylation in vivo. Epigenetics 8, 477-85 23644510 Curated Info
8	Rikova K (2012) CST Curation Set: 16504; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
9	Rikova K (2012) CST Curation Set: 16501; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
10	Rikova K (2012) CST Curation Set: 16502; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
11	Rikova K (2012) CST Curation Set: 16503; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
12	Mulhern D (2012) CST Curation Set: 14368; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
13	Tucker M (2010) CST Curation Set: 9906; Year: 2010; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
14	Tucker M (2010) CST Curation Set: 9897; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
15	Tucker M (2010) CST Curation Set: 9911; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
16	Tucker M (2010) CST Curation Set: 9898; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
17	Tucker M (2010) CST Curation Set: 9905; Year: 2010; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
18	Tucker M (2010) CST Curation Set: 9904; Year: 2010; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
19	Tucker M (2010) CST Curation Set: 9909; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
20	Tucker M (2010) CST Curation Set: 9901; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
21	Tucker M (2010) CST Curation Set: 9899; Year: 2010; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
22	Tucker M (2010) CST Curation Set: 9900; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
23	Possemato A (2009) CST Curation Set: 8360; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info
24	Possemato A (2009) CST Curation Set: 8353; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1K Curated Info